Galantos Pharma Overview

  • Founded
  • 2005
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Galantos Pharma General Information

Description

Developer of novel drugs for the treatment of Alzheimer's Disease and other neurodegenerative diseases. The company is developing Memogain, a derivative of the plant alkaloid galantamine, for symptomatic and disease-modifying treatment of Alzheimer's dementia (AD).

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Hinter der Hecke 1
  • 55268 Nieder-Olm
  • Germany
+49 06136 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Galantos Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 04-Sep-2013 00.000 Completed Generating Revenue
4. Later Stage VC (Series C) 30-Apr-2010 00.000 00.000 Completed Generating Revenue
3. Grant 30-Jun-2009 00.000 000 Completed Generating Revenue
2. Early Stage VC (Series B) 06-Sep-2007 $1M Completed Generating Revenue
1. Early Stage VC (Series A) $1M $1M Completed
To view Galantos Pharma’s complete valuation and funding history, request access »

Galantos Pharma Executive Team (3)

Name Title Board Seat Contact Info
Alfred Maelicke Ph.D Chief Executive Officer & Co-Founder
Ulrich Jordis Co-Founder
You’re viewing 2 of 3 executive team members. Get the full list »

Galantos Pharma Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Co-Investor Growth/Expansion Minority 000 0000 000000 0
EVP Capital Management Growth/Expansion Minority 000 0000 000000 0
High-Tech Gründerfonds Venture Capital Minority 000 0000 000000 0
Investitions- und Strukturbank Rheinland-Pfalz Venture Capital Minority 000 0000 000000 0
KfW IPEX-Bank Investment Bank Minority 000 0000 000000 0
To view Galantos Pharma’s complete investors history, request access »